Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists

被引:11
|
作者
Drabczynska, Anna [1 ]
Zygmunt, Malgorzata [2 ]
Sapa, Jacek [2 ]
Filipek, Barbara [2 ]
Mueller, Christa E. [3 ]
Kiec-Kononowicz, Katarzyna [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Technol & Biotechnol Drugs, Fac Pharm, PL-30688 Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Dept Pharmacol, PL-30688 Krakow, Poland
[3] Univ Bonn, PharmaCtr Bonn, Inst Pharmaceut, D-5300 Bonn, Germany
关键词
Antiparkinsonian activity; Adenosine A(2A) receptors; Pyrimido[2,1-f]purinedione; Pyrazino[2,1-f]purinedione; Xanthines; PARKINSONS-DISEASE; LIGANDS; A(1); ISTRADEFYLLINE; THERAPIES; PD;
D O I
10.1002/ardp.201000124
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The present work describes the synthesis of a pyrazinopurinedione derivative which was together with a series of pyrimidopurinedione derivatives tested for potential antiparkinsonian activity in two tests: the "oxotremorine" and the "reserpine" test. For the studies compounds which had shown affinity for the adenosine A(2A) receptor were chosen. One compound, a pyrazinopurinedione derivative, without affinity for A(2A) receptors, but showing adenosine A(1) receptor affinity was also investigated. The performed preliminary tests indicated that, contrary to the pyrazinopurinedione all pyrimidopurinediones demonstrated antiparkinsonian effects. As a result of present studies it may be concluded that antiparkinsonian effects of the examined compounds are correlated with the antagonistic activity toward adenosine A(2A) receptors in this class of compounds. However a direct correlation of the potency of both effects was not observed possibly due to different pharmacokinetic properties of the compounds. The most active derivatives of the present series were aryl-substituted pyrimidopurinediones.
引用
收藏
页码:20 / 27
页数:8
相关论文
共 50 条
  • [1] Involvement of globus pallidus in the antiparkinsonian effects of adenosine A2A receptor antagonists
    Simola, Nicola
    Fenu, Sandro
    Baraldi, Pier G.
    Tabrizi, Moigan Aghazadeh
    Morelli, Micaela
    [J]. EXPERIMENTAL NEUROLOGY, 2006, 202 (01) : 255 - 257
  • [2] Anti-inflammatory, antioxidant, and antiparkinsonian effects of adenosine A2A receptor antagonists
    Zygmunt, Malgorzata
    Golembiowska, Krystyna
    Drabczynska, Anna
    Kic-Kononowicz, Katarzyna
    Sapa, Jacek
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2015, 132 : 71 - 78
  • [3] The discovery and synthesis of novel adenosine receptor (A2A) antagonists
    Matasi, JJ
    Caldwell, JP
    Hao, JS
    Neustadt, B
    Arik, L
    Foster, CJ
    Lachowicz, J
    Tulshian, DB
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) : 1333 - 1336
  • [4] Selective adenosine A2A receptor antagonists
    Ongini, E
    Monopoli, A
    Cacciari, B
    Baraldi, PG
    [J]. FARMACO, 2001, 56 (1-2): : 87 - 90
  • [5] Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening
    Langmead, Christopher J.
    Andrews, Stephen P.
    Congreve, Miles
    Errey, James C.
    Hurrell, Edward
    Marshall, Fiona H.
    Mason, Jonathan S.
    Richardson, Christine M.
    Robertson, Nathan
    Zhukov, Andrei
    Weir, Malcolm
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) : 1904 - 1909
  • [6] Adenosine A2A receptor antagonists as a novel non-dopaminergic therapy for Parkinson's disease: A potential mechanism of the antiparkinsonian action
    Mori, A.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 319 - 319
  • [7] Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists
    Laversin, Amelie
    Dufossez, Robin
    Bolteau, Raphael
    Duroux, Romain
    Ravez, Severine
    Hernandez-Tapia, Sergio
    Fossart, Martin
    Coevoet, Mathilde
    Liberelle, Maxime
    Yous, Said
    Lebegue, Nicolas
    Melnyk, Patricia
    [J]. MOLECULES, 2024, 29 (16):
  • [8] Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists
    Szabo, Nikoletta
    Kincses, Zsigmond Tamas
    Vecsei, Laszlo
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (04) : 441 - 455
  • [9] Design, synthesis, and biological evaluation of novel adenosine A2A receptor antagonists
    Silverman, LS
    Caldwell, J
    Greenlee, WJ
    Kiselgof, EY
    Matasi, J
    Tuishian, D
    Arik, L
    Foster, C
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2548 - U2549
  • [10] Novel investigational adenosine A2A receptor antagonists for Parkinson's disease
    Pinna, Annalisa
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1619 - 1631